Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | CD69 | Q07108 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18949167 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL18949157 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL18949217 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL18949083 | 0.98 | ADRA2A (0.42) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL12903040 | 0.96 | ADRA2A (0.40) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL12398688 | 0.83 | ADRA2A (0.32) | ADRA2AADRA2BADRA2CTP53 | |
| SCHEMBL19682255 | 0.81 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CNOS3NOS1 | |
| SCHEMBL18949084 | 0.81 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CCDK5CDK5R1 | |
| SCHEMBL18949087 | 0.81 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CCDK5CDK5R1 | |
| SCHEMBL12398696 | 0.81 | ADRA2A (0.33) | ADRA2AADRA2BADRA2CGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-07-20 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-9718821-B2 | Pyridopyrimidinone inhibitors of kinases | ABBVIE INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-15 | — | — | US | disclosed |
| US-9051327-B2 | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20110269953-A1 | Nitrogen and Sulfur-Containing Heterocycle Derivatives | ARMILLI MURTY N | 2011-11-03 | — | — | US | disclosed |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | NEUROGEN CORPORATION | 2011-01-06 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662830-B2 | Substituted biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2010-02-16 | — | — | US | disclosed |
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | NEUROGEN CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-7566712-B2 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | NEUROGEN CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105865-A1 | Substituted bicyclic quinazolin-4-ylamine derivatives | PIGS, HRH4, GPR35 | ADRA2A 45/4885ADRA2B 95/4885ADRA2C 25/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | ADRA2A 3899/4885ADRA2B 4178/4885ADRA2C 4433/4885 |
| US-20110003813-A1 | SUBSTITUTED BIARYL PIPERAZINYL-PYRIDINE ANALOGUES | GPR88, PIGO, PRLHR | ADRA2A 73/4885ADRA2B 76/4885ADRA2C 74/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | ADRA2A 168/4885ADRA2B 294/4885ADRA2C 481/4885 |
| US-20190169164-A1 | BENZAZEPINE COMPOUNDS, CONJUGATES, AND USES THEREOF | TLR8, TLR3, TLR5 | ADRA2A 796/4885ADRA2B 880/4885ADRA2C 662/4885 |
| US-20100008866-A1 | CIS-CYCLOHEXYL SUBSTITUTED PYRIMIDINONE DERIVATIVES | PIGS, GPR174, GPR17 | ADRA2A 119/4885ADRA2B 129/4885ADRA2C 103/4885 |
| US-20160264566-A1 | ANTI-ALPHAVBETA1 INTEGRIN INHIBITORS AND METHODS OF USE | ITGB1, ITGA1, ITGAV | ADRA2A 488/4885ADRA2B 274/4885ADRA2C 932/4885 |
| US-20180177784-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | ADRA2A 2829/4885ADRA2B 3180/4885ADRA2C 2627/4885 |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | ADRA2A 78/4885ADRA2B 85/4885ADRA2C 84/4885 |
| US-20110269953-A1 | Nitrogen and Sulfur-Containing Heterocycle Derivatives | TST, HNMT, HRH4 | ADRA2A 1828/4885ADRA2B 1395/4885ADRA2C 748/4885 |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | ADRA2A 69/4885ADRA2B 77/4885ADRA2C 63/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | ADRA2A 168/4885ADRA2B 294/4885ADRA2C 481/4885 |
| US-20230226062-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | ADRA2A 2829/4885ADRA2B 3180/4885ADRA2C 2627/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | ADRA2A 253/4885ADRA2B 217/4885ADRA2C 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.